Randomized, double blind trial to evaluate the safety and efficacy of metformin vs placebo plus neoadjuvant chemotherapy in locally advanced breast cancer.

Arce-Salinas, Claudia; Alamilla, Gabriela; Flores-Díaz, D; Deneken, Connie Zuratzi; Mendoza-Galindo, Leticia; Ramírez-Morales, Rebeca; Shaw-Dulin, Robin; Santamaria-Galicia, Julieta; Alvarado‐Miranda, Alberto; Villarreal‐Garza, Cynthia; Galeana, Paula Cabrera

doi:10.1200/jco.2016.34.15_suppl.579

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main finding of our study is that the rate of complete pathological response was 14.8% (4 patients) in group (A) "Metformin group" versus 6.3% (2 patients) in group (B) "non-metformin group" with a p-value of 0.39 which is comparable to what was published by Arce-Salinas et al in 2016 30 where they carried out a randomized double-blinded trial included (48) hormonal positive & Her-2 negative non-diabetic breast cancer patients. Twenty-eight patients received neoadjuvant chemotherapy (Anthracyclin and Taxanes) with Metformin 850 mg BID and 20 patients in the control arm received neoadjuvant chemotherapy without Metformin.…”

Section: Discussionsupporting

confidence: 88%

The Effect of Metformin When Combined With Neoadjuvant Chemotherapy in Breast Cancer Patients

El-Khayat

Abouegylah

Abdallah

et al. 2021

Preprint

View full text Add to dashboard Cite

BackgroundMetformin has been used to treat type 2 Diabetes Mellitus since long time. It has two proposed anti-neoplastic mechanisms, direct (insulin-independent) and indirect (insulin-dependent) actions. PurposeTo assess the effect of Metformin on pathological response when combined with neoadjuvant chemotherapy in breast cancer. Material and MethodsA prospective study included stage II, III non-diabetic breast cancer patients who received neoadjuvant chemotherapy in our center during the period from May 2017 to March 2019. 59 patients met our inclusion criteria and completed the study, 27 patients received 850mg Metformin every 12 hrs with chemotherapy (group A), 32 patients received chemotherapy without Metformin (group B). Pathological response was assessed by Chevallier classification and residual cancer burden score (RCB). ResultsBoth groups were well balanced regarding base line characteristics. The results of our study showed that the rate of pathological complete response (pCR) was 14.8% in group (A) vs. 6.3% in group (B) with a P-value of 0.39. RCB class 3 was 40.7% in group (A) Vs. 68.8% in group (B) which was statistically significant with a (P-value of 0.031). Patients with triple-positive histology who had RCB class 3 were only (14.3%) in group (A) versus (60%) in group B. Patients with body mass index (BMI) ≥25 who had RCB 3 were 40% and 66.7% in group (A) and (B) respectively. ConclusionMetformin may increase the pCR especially in patients with BMI≥25 and patients with triple-positive histology, a larger phase III study is needed to confirm this finding.

show abstract

Section: Discussionsupporting

confidence: 88%